摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-哌嗪酮,1-(4-吡啶基)- | 374795-64-9

中文名称
2-哌嗪酮,1-(4-吡啶基)-
中文别名
1-(4-吡啶基)-哌嗪-2-酮
英文名称
1-(Pyridin-4-YL)piperazin-2-one
英文别名
1-pyridin-4-ylpiperazin-2-one
2-哌嗪酮,1-(4-吡啶基)-化学式
CAS
374795-64-9
化学式
C9H11N3O
mdl
MFCD07373445
分子量
177.2
InChiKey
YICVQHIYWACOHK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    432.5±35.0 °C(Predicted)
  • 密度:
    1.201±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -0.4
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.333
  • 拓扑面积:
    45.2
  • 氢给体数:
    1
  • 氢受体数:
    3

文献信息

  • Quinoline derivatives as neurokinin receptor antagonists
    申请人:Carling William Robert
    公开号:US20090054440A1
    公开(公告)日:2009-02-26
    The present invention relates to substituted quinoline hydrazides of Formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 , X, Y and Z are defined herein, pharmaceutical compositions comprising them and their use in treating diseases mediated by neurokinin-2 and/or neurokinin-3 (NK-3) receptors. These compounds can thus be used in methods of treatment to suppress and treat such disorders.
    本发明涉及式(I)所示的取代喹啉酰肼:其中R1、R2、R3、R4、R5、X、Y和Z在此定义,包含它们的药物组合物及其在治疗由神经激肽-2和/或神经激肽-3 (NK-3)受体介导的疾病中的用途。因此,这些化合物可用于治疗方法,以抑制和治疗这些疾病。
  • Cyclohexane derivatives and their use as therapeutic agents
    申请人:——
    公开号:US20030236250A1
    公开(公告)日:2003-12-25
    The present invention relates compounds of formula (I), wherein ring A is a phenyl or pyridyl ring; X represents a linker selected from the group consisting of formulae: (a), (b), (c), (d), and (e); and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 13 , R 14 , R 15 , R 16 , R 17 , R 21a and R 21b are as defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia. 1
    本发明涉及式(I)的化合物,其中环A是苯环或吡啶环;X代表从以下式组成的选择性连接物:(a)、(b)、(c)、(d)和(e);以及R1、R2、R3、R4、R5、R6、R7、R13、R14、R15、R16、R17、R21a和R21b如本文所定义。这些化合物特别适用于治疗或预防抑郁症、焦虑、疼痛、炎症、偏头痛、呕吐或带状疱疹后神经痛。
  • [EN] PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE<br/>[FR] DÉRIVÉS DE PYRIMIDONE ET LEUR UTILISATION POUR LE TRAITEMENT, LA PRÉVENTION OU L'ATTÉNUATION DES SYMPTÔMES D'UNE MALADIE VIRALE
    申请人:SAVIRA PHARMACEUTICALS GMBH
    公开号:WO2017158147A1
    公开(公告)日:2017-09-21
    The present invention relates to a compound having the general formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease, in particular influenza.
    本发明涉及具有通式(I)的化合物,可选地以药学上可接受的盐、溶剂合物、多晶形、共药、共晶、前药、互变异构体、消旋体、对映体或二对映体或其混合物的形式存在,用于治疗、缓解或预防病毒性疾病,特别是流感。
  • [EN] CYCLOHEXANE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS<br/>[FR] DERIVES DE CYCLOHEXYLE ET LEUR UTILISATION COMME AGENTS THERAPEUTIQUES
    申请人:MERCK SHARP & DOHME
    公开号:WO2001087838A1
    公开(公告)日:2001-11-22
    The present invention relates compounds of formula (I), wherein ring A is a phenyl or pyridyl ring; X represents a linker selected from the group consisting of formulae: (a), (b), (c), (d), and (e); and R?1, R2, R3, R4, R5, R6, R7, R13, R14, R15, R16, R17, R21a and R21b¿ are as defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia.
    本发明涉及公式(I)的化合物,其中环A是苯环或吡啶环;X代表从公式(a)、(b)、(c)、(d)和(e)组成的链连接物;R?1、R2、R3、R4、R5、R6、R7、R13、R14、R15、R16、R17、R21a和R21b¿如本文所定义。该化合物特别适用于治疗或预防抑郁症、焦虑症、疼痛、炎症、偏头痛、呕吐或带状疱疹后神经痛。
  • CYCLOHEXANE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS
    申请人:MERCK SHARP & DOHME LTD.
    公开号:EP1286967B1
    公开(公告)日:2006-09-27
查看更多